The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical giant, for its drug Esperoct (turoctocog alfa pegol). This marks Esperoct as the first and only long-acting recombinant coagulation factor VIII approved in China for on-demand treatment and control of bleeding events, as well as for perioperative management and routine preventive treatment in children and adults aged 12 and above with hemophilia A. The drug is intended to prevent or reduce the occurrence of bleeding events in this patient population.
Esperoct is a covalent conjugate consisting of recombinant human coagulation factor and 40kDa polyethylene glycol (PEG) molecules. It represents an innovative approach to the treatment of hemophilia A. The drug has also been registered in the US, Canada, Italy, Japan, and several other countries.- Flcube.com
